PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness

Ahrens, Michael J.; Bertin, Paul; Vonesh, Edward F.; Meade, Thomas J.; Catàlona, William J.; Georganopoulou, Dimitra G.

doi:10.1002/pros.22714

Cited by 19 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, treatment with BIM-23926 sst1 agonist did not alter AR phosphorylation, which could suggest that SSTR1 is tightly associated with AR pathway, but not directly through the activation of AR phosphorylation. Furthermore, treatment with BIM-23926 sst1 agonist during 24h decreased PSA secretion in 22Rv1 cell line, which reinforces the potential role of SSTR1 in the prostate, since PSA is over-secreted in PCa 68 and clearly associated to AR activity. 69 In this sense, the role of sst1 in the modulation of AR activity in PCa, as well as its putative role in castration resistant PCa warrant further investigation.…”

Section: Discussionsupporting

confidence: 66%

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 66%

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…As for in vivo tPSA activity, we utilized human PCa specimens, demonstrating a correspondence between higher tPSA protein expression and low-to-null COL1A1 expression, paralleled by high COL1A1 cleavage; this envisages PSA per se is enzymatically active in the tumor milieu. Notably, PSA activity measured in prostate tissue has been previously reported to be inversely correlated to tumor aggressiveness and PCa cell invasive abilities [ 16 , [29] , [30] , [31] ]. In addition, our dataset analysis highlighted a consistent inverse correlation between KLK3 and several types of collagens, including COL1A1.…”

Section: Discussionmentioning

confidence: 99%

A mechanistic insight into the anti-metastatic role of the prostate specific antigen

Pellegrino

Coghi

Lavorgna

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

Highlights Prostate specific antigen is the standard circulating biomarker for prostate cancer. We provide novel evidence that collagen 1 is an additional substrate for PSA. PSA hampers first steps of cancer invasion. Tissue-related PSA content/activity is inversely correlated to tumor progression. Tissue-related PSA levels improve prediction of prostate cancer specific mortality.

show abstract

“…Bioactivated MR agents can be utilized to report enzymatic activities [43, 44], gene expression ( e.g. , β-galactosidase [45], β-glucoronidase, caspases [46], metalloproteinases (MMPs) ( e.g.…”

Section: Advances In Molecular Probe Designmentioning

confidence: 99%

NIH Workshop on Clinical Translation of Molecular Imaging Probes and Technology—Meeting Report

et al. 2014

View full text Add to dashboard Cite

A workshop on “Clinical Translation of Molecular Imaging Probes and Technology” was held August 2, 2013 in Bethesda, Maryland, organized and supported by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). This workshop brought together researchers, clinicians, representatives from pharmaceutical companies, molecular probe developers, and regulatory science experts. Attendees met to talk over current challenges in the discovery, validation, and translation of molecular imaging (MI) probes for key clinical applications. Participants also discussed potential strategies to address these challenges. The workshop consisted of 4 sessions, with 14 presentations and 2 panel discussions. Topics of discussion included (1) challenges and opportunities for clinical research and patient care, (2) advances in molecular probe design, (3) current approaches used by industry and pharmaceutical companies, and (4) clinical translation of MI probes. In the presentations and discussions, there were general agreement that while the barriers for validation and translation of MI probes remain high, there are pressing clinical needs and development opportunities for targets in cardiovascular, cancer, endocrine, neurological, and inflammatory diseases. The strengths of different imaging modalities, and the synergy of multimodality imaging, were highlighted. Participants also underscored the continuing need for close interactions and collaborations between academic and industrial partners, and federal agencies in the imaging probe development process.

show abstract

PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness

Cited by 19 publications

References 37 publications

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer

A mechanistic insight into the anti-metastatic role of the prostate specific antigen

NIH Workshop on Clinical Translation of Molecular Imaging Probes and Technology—Meeting Report

Contact Info

Product

Resources

About